Targeting phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in breast cancer and fibroblast growth factor 3 (FGFR3) in urothelial cancer was attempted in clinical trials, e.g., NCT04524000 and NCT03390504, and is now approved for metastatic disease in these cancer types. Here, PIK3CA is linked to breast cancer.